Jokl R, Klein R L, Lopes-Virella M F, Colwell J A
Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina 29401, USA.
Diabetes Care. 1995 Aug;18(8):1150-5. doi: 10.2337/diacare.18.8.1150.
To compare platelet plasminogen activator inhibitor 1 (PAI-1) release in type II diabetic patients and healthy control subjects.
We studied a group of 27 diabetic patients and a group of 16 nondiabetic control subjects. Whole-blood platelet aggregation, defined as a decrease in platelet count during shaking (180 rpm) of blood samples at 37 degrees C, and plasma PAI-1 antigen concentrations were measured in parallel at time 0, 7.5, 15, 30, 60, 120, and 180 min.
Platelet aggregation did not differ significantly between the two groups at any time period. However, the increase in plasma PAI-1 antigen concentration over basal levels at time 0 was higher for the group of diabetic patients when compared with their matched control subjects. The increment of PAI-1 antigen was 61.8 +/- 29.4 vs. 35.9 +/- 13.4 ng/ml (P < 0.005, means +/- SD) after 180 min for the diabetic and control subjects, respectively. Platelet PAI-1 release was correlated to very-low-density lipoprotein cholesterol and triglyceride plasma levels, but not to HbA1c levels.
Platelets of patients with type II diabetes release significantly more PAI-1 than platelets of healthy subjects at the same level of platelet aggregation. This may contribute to enhanced thrombosis in diabetes.
比较2型糖尿病患者和健康对照者血小板纤溶酶原激活物抑制剂1（PAI-1）的释放情况。
我们研究了一组27名糖尿病患者和一组16名非糖尿病对照者。在37℃下对血样进行振荡（180转/分钟）时，全血血小板聚集定义为血小板计数的减少，并在0、7.5、15、30、60、120和180分钟时平行测量血浆PAI-1抗原浓度。
两组在任何时间段血小板聚集均无显著差异。然而，与匹配的对照者相比，糖尿病患者组在0时血浆PAI-1抗原浓度相对于基础水平的增加更高。糖尿病患者和对照者在180分钟后PAI-1抗原的增量分别为61.8±29.4和35.9±13.4 ng/ml（P<0.005，均值±标准差）。血小板PAI-1释放与极低密度脂蛋白胆固醇和血浆甘油三酯水平相关，但与糖化血红蛋白水平无关。
在相同血小板聚集水平下，2型糖尿病患者的血小板释放的PAI-1明显多于健康受试者的血小板。这可能有助于糖尿病患者血栓形成增加。
